(NASDAQ: GLTO) Galecto's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 62.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.
Galecto's earnings in 2026 is -$15,844,000.On average, 4 Wall Street analysts forecast GLTO's earnings for 2026 to be -$1,732,808, with the lowest GLTO earnings forecast at -$2,029,042, and the highest GLTO earnings forecast at -$1,393,573.
In 2027, GLTO is forecast to generate -$2,477,374 in earnings, with the lowest earnings forecast at -$2,939,509 and the highest earnings forecast at -$1,951,002.